Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ABBV

AbbVie (ABBV)

AbbVie Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:ABBV
日付受信時刻ニュースソース見出しコード企業名
2024/04/2620 : 47IH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
2024/04/2620 : 35PR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
2024/04/2521 : 00PR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
2024/04/2321 : 00PR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
2024/04/1821 : 31PR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
2024/04/1220 : 30PR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
2024/04/0921 : 00PR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
2024/04/0421 : 00PR Newswire (US)AbbVie to Host First-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
2024/04/0321 : 30PR Newswire (US)Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®NYSE:ABBVAbbVie Inc
2024/04/0120 : 50GlobeNewswire Inc.NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-YearNYSE:ABBVAbbVie Inc
2024/03/2620 : 20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNYSE:ABBVAbbVie Inc
2024/03/2600 : 00PR Newswire (US)Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in AestheticsNYSE:ABBVAbbVie Inc
2024/03/2521 : 31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
2024/03/2521 : 30GlobeNewswire Inc.AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
2024/03/2304 : 02PR Newswire (US)U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer PatientsNYSE:ABBVAbbVie Inc
2024/03/2121 : 00PR Newswire (US)ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024NYSE:ABBVAbbVie Inc
2024/03/0722 : 00PR Newswire (US)AbbVie to Present at the Barclays 26th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
2024/03/0622 : 03PR Newswire (US)AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics PortfoliosNYSE:ABBVAbbVie Inc
2024/03/0607 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
2024/03/0602 : 09PR Newswire (Canada)Dragonfly a reçu un paiement d'étape à la suite de la prise de dose du premier patient à l'essai clinique de phase 1 d'AbbVie évaluant le DF4101/ABBV-303NYSE:ABBVAbbVie Inc
2024/03/0522 : 00PR Newswire (US)JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA ApprovalNYSE:ABBVAbbVie Inc
2024/03/0521 : 00PR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
2024/03/0521 : 00PR Newswire (Canada)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
2024/03/0521 : 00PR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
2024/03/0209 : 53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
2024/03/0207 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
2024/03/0207 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
2024/03/0207 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
2024/03/0207 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
2024/03/0207 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV

最近閲覧した銘柄